NHS Continuing Healthcare Support
Make your next CHC step clearer. Nellie Supports helps families and professionals in England prepare for assessments, present evidence and challenge decisions. You receive independent s…
Read moreGUIDES
Cancer can lead to care needs from the illness, treatment or both. CHC eligibility depends on those needs. Fast Track is appropriate where an appropriate clinician identifies a rapidly deteriorating condition that may be entering a terminal phase; a cancer diagnosis alone does not decide the route.
Cancer can lead to care needs from the illness, treatment or both. CHC eligibility depends on those needs. Fast Track is appropriate where an appropriate clinician identifies a rapidly deteriorating condition that may be entering a terminal phase; a cancer diagnosis alone does not decide the route.
Where the condition is deteriorating rapidly and may be entering a terminal phase, an appropriate clinician can complete a Fast Track Pathway Tool and funding should follow urgently, with no Checklist or Decision Support Tool required. Oncology and palliative care teams complete many of these. Where the trajectory is clear, this is by far the quicker route.
If the Fast Track criteria are not met but needs may indicate a primary health need, ask about the standard CHC route. Living longer with advanced cancer or continuing active treatment does not itself exclude Fast Track. The appropriate clinician should consider the current trajectory and anticipated needs, without imposing a fixed remaining-life limit.
Treatment may cause needs such as fatigue, neuropathy, lymphoedema, nausea or infection risk. Record those actually present, how long they last and the care required across treatment cycles. Short-term or recovering needs may affect when CHC assessment is appropriate, but interim clinical and care support should still be addressed.
Pain, nausea, breathlessness and agitation may require complex regimes, frequent as required medication and repeated adjustment. Where a syringe driver is in use, that requires trained management and monitoring. Difficult symptom control engages the medication domain, which can reach priority, and speaks to nature and complexity.
Bone metastases bringing fracture risk and pain, brain metastases bringing cognitive change, seizures and behavioural change, spinal cord compression, malignant wounds requiring specialist dressing, and lymphoedema management. Each engages specific domains and each is frequently recorded only in clinical correspondence rather than in the assessment.
A person may be reasonably independent early in a cycle and highly dependent later, which is a fluctuation pattern assessments regularly miss. State where in the cycle the assessment took place and describe the range across the whole cycle rather than the day of the meeting.
Ask about Fast Track first where the trajectory is deteriorating. Where it is not, use the standard route rather than waiting. Record treatment effects and cycle fluctuation, and carry the needs from advanced disease out of clinical letters and into the domains.
Where the condition is deteriorating rapidly and may be entering a terminal phase, yes, and oncology or palliative care teams complete many of these tools. Where the trajectory is not rapid, the standard route applies.
Ask the treating clinician whether the Fast Track criteria apply now. If they do not, and ongoing needs may indicate CHC eligibility, ask for the standard route to be considered. A Checklist or DST must not delay action on a valid Fast Track tool.
Yes, describe the side effects actually present and their effect on care needs, including duration and variation across a treatment cycle. The assessment timing may need to distinguish short-term recovery from ongoing needs. Required support should still be arranged while that is considered.
Include its care and monitoring requirements and the person’s symptom-control needs. A syringe driver alone does not determine the medication-domain level. The descriptor must fit the actual symptoms, response to treatment, monitoring and professional intervention required.
State where in the cycle the assessment occurred and describe the range across the whole cycle, since assessments frequently capture the better part of it.
Ask the oncology or palliative care team to explain current needs, likely changes and whether the Fast Track criteria apply. Provide a representative record across treatment cycles and the current symptom-control plan. Do not assume either ongoing treatment or a cancer diagnosis decides the funding route.
These pages explain related stages of the NHS Continuing Healthcare process in England. The service page describes optional paid support.
NHS Continuing Healthcare Support
What rapidly deteriorating means
The drug therapies and medication domain
Why a diagnosis alone does not decide CHC eligibility
Department of Health and Social Care (2022) National Framework for NHS Continuing Healthcare and NHS-funded Nursing Care. Available at: https://www.gov.uk/government/publications/national-framework-for-nhs-continuing-healthcare-and-nhs-funded-nursing-care
Department of Health and Social Care (2022) NHS Continuing Healthcare Decision Support Tool.
National Institute for Health and Care Excellence. Clinical guidance. Available at: https://www.nice.org.uk
R v North and East Devon Health Authority, ex parte Coughlan [2000] 2 WLR 622.
Written by Ben Slater, Registered Social Worker, Founder and Managing Director of Nellie Supports
Reviewed by Kerry Slater, Director of Operations
Last reviewed: 2026-07-20
Author: Ben Slater, Registered Social Worker, Founder and Managing Director of Nellie SupportsReviewed by: Kerry Slater, Director of OperationsLast reviewed: 20 July 2026
1. Department of Health and Social Care (2022) National Framework for NHS Continuing Healthcare and NHS-funded Nursing Care. Available at: https://www.gov.uk/government/publications/national-framework-for-nhs-continuing-healthcare-and-nhs-funded-nursing-care2. Department of Health and Social Care (2022) NHS Continuing Healthcare Decision Support Tool.3. National Institute for Health and Care Excellence. Clinical guidance. Available at: https://www.nice.org.uk4. R v North and East Devon Health Authority, ex parte Coughlan [2000] 2 WLR 622.
Copyright © 2026 Nellie Supports Ltd. All rights reserved.
This article is made available for general information, education and professional reference. It may be downloaded, printed and shared for non-commercial purposes, provided that it is reproduced in full, is not altered in any way, and is properly cited as the work of Nellie Supports Ltd. This material must not be edited, adapted, sold, republished, incorporated into commercial products, or used for commercial training, assessment, report-writing or advisory services without prior written permission from Nellie Supports Ltd.
This article does not constitute legal advice, clinical advice or a substitute for a decision-specific professional assessment. Where legislation, government guidance, court forms or external professional materials are referred to, those materials remain subject to their own copyright, licensing and re-use terms.
This guide explains how NHS Continuing Healthcare eligibility is assessed where a person has cancer. It covers when the Fast Track route applies, the position for people living with cancer over a longer period, treatment effects, symptom control, the needs arising from advanced disease, and the evidence that supports an accurate assessment.
This guide covers NHS Continuing Healthcare in England. Ask the ICB's continuing healthcare team about the next stage and any local forms or deadlines. For an enquiry to Nellie Supports, call 0333 987 5118. You do not need to buy private support to request an NHS assessment or challenge a decision.
A GOOD PLACE TO START
Tell us what is happening and what you need help with. We will listen, explain the options and help you find the right starting point.